Drugs that contain Methotrexate Sodium
1. Xatmep patents expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US11116724 | AZURITY | Methotrexate composition |
Jan, 2033
(8 years from now) | |
| US10610485 | AZURITY | Methotrexate composition |
Jan, 2033
(8 years from now) | |
| US9855215 | AZURITY | Methotrexate composition |
Jan, 2033
(8 years from now) | |
| US9259427 | AZURITY | Methotrexate composition |
Jan, 2033
(8 years from now) | |
| US10231927 | AZURITY | Methotrexate composition |
Jan, 2033
(8 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| Orphan Drug Exclusivity(ODE-137) | Apr 25, 2024 |
| Orphan Drug Exclusivity(ODE-138) | Apr 25, 2024 |
| Orphan Drug Exclusivity(ODE) | Apr 25, 2024 |
Market Authorisation Date: 25 April, 2017
Treatment: A method for treating acute lymphoblastic leukemia; Treatment of juvenile rheumatoid arthritis
Dosage: SOLUTION;ORAL
More Information on Dosage
XATMEP family patents
